Johnson & Johnson $JNJ Stock Sold by PBU The Pension Fund of Early Childhood & Youth Educators

PBU The Pension Fund of Early Childhood & Youth Educators lowered its holdings in Johnson & Johnson (NYSE:JNJ) by 10.2% during the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 143,457 shares of the company’s stock after selling 16,320 shares during the quarter. Johnson & Johnson accounts for 0.9% of PBU The Pension Fund of Early Childhood & Youth Educators’ holdings, making the stock its 23rd largest holding. PBU The Pension Fund of Early Childhood & Youth Educators’ holdings in Johnson & Johnson were worth $37,979,000 as of its most recent SEC filing.

Other large investors have also modified their holdings of the company. Werba Rubin Papier Wealth Management raised its position in Johnson & Johnson by 7.2% in the third quarter. Werba Rubin Papier Wealth Management now owns 4,627 shares of the company’s stock valued at $1,225,000 after purchasing an additional 310 shares during the period. Van Strum & Towne Inc. boosted its position in shares of Johnson & Johnson by 1.0% during the third quarter. Van Strum & Towne Inc. now owns 45,074 shares of the company’s stock worth $11,933,000 after buying an additional 442 shares during the period. Austin Wealth Management LLC grew its stake in shares of Johnson & Johnson by 10.8% in the third quarter. Austin Wealth Management LLC now owns 1,972 shares of the company’s stock valued at $506,000 after buying an additional 193 shares in the last quarter. CENTRAL TRUST Co grew its stake in shares of Johnson & Johnson by 0.4% in the third quarter. CENTRAL TRUST Co now owns 115,152 shares of the company’s stock valued at $30,485,000 after buying an additional 449 shares in the last quarter. Finally, Artemis Wealth Advisors LLC raised its holdings in shares of Johnson & Johnson by 44.7% in the 3rd quarter. Artemis Wealth Advisors LLC now owns 2,315 shares of the company’s stock valued at $613,000 after buying an additional 715 shares during the period. Institutional investors and hedge funds own 69.55% of the company’s stock.

Insider Activity

In related news, EVP Timothy Schmid sold 33,597 shares of the company’s stock in a transaction that occurred on Wednesday, September 2nd. The shares were sold at an average price of $274.74, for a total transaction of $9,230,439.78. Following the sale, the executive vice president directly owned 25,447 shares in the company, valued at approximately $6,991,308.78. This represents a 56.90% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Jennifer L. Taubert sold 15,000 shares of the firm’s stock in a transaction that occurred on Monday, August 17th. The shares were sold at an average price of $263.36, for a total transaction of $3,950,400.00. Following the completion of the sale, the executive vice president directly owned 194,451 shares in the company, valued at approximately $51,210,615.36. This trade represents a 7.16% decrease in their position. The SEC filing for this sale provides additional information. Company insiders own 0.16% of the company’s stock.

Key Johnson & Johnson News

These are some of the JNJ news items that stood out recently:

• Neutral Sentiment: State Street’s Health Care SPDR added J&J shares on Nov. 10 as part of a broader increase across all of the fund’s holdings. The purchase provides an institutional-demand datapoint but was not specific to J&J. State Street Health Care SPDR adds Johnson & Johnson
• Negative Sentiment: A Massachusetts jury awarded $3.3 million to the family of a woman who developed mesothelioma after using J&J talc-based baby powder. The award adds to ongoing talc-related litigation exposure. Massachusetts woman’s family awarded $3.3 million against Johnson & Johnson
• Negative Sentiment: Pomerantz LLP said it is investigating potential claims on behalf of J&J investors. The announcement does not establish wrongdoing or the outcome of any claims, but adds another legal headline for investors to monitor. Pomerantz law firm investigates claims on behalf of J&J investors

Johnson & Johnson Stock Up 1.2%

Johnson & Johnson stock opened at $283.69 on Friday. Johnson & Johnson has a twelve month low of $193.45 and a twelve month high of $286.08. The stock’s fifty day simple moving average is $266.83 and its 200-day simple moving average is $249.54. The company has a current ratio of 1.02, a quick ratio of 0.74 and a debt-to-equity ratio of 0.44. The firm has a market capitalization of $682.93 billion, a P/E ratio of 42.98, a P/E/G ratio of 2.77 and a beta of 0.22.

Johnson & Johnson (NYSE:JNJ) last released its earnings results on Tuesday, October 13th. The company reported $2.59 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.53 by $0.06. Johnson & Johnson had a return on equity of 31.64% and a net margin of 16.20%. The firm had revenue of $25.40 billion during the quarter, compared to analyst estimates of $25.38 billion. During the same period last year, the business posted $2.80 earnings per share. Johnson & Johnson’s revenue was up 5.9% compared to the same quarter last year. Johnson & Johnson has set its FY 2026 guidance at 11.050-11.150 EPS. As a group, equities analysts expect that Johnson & Johnson will post 11.12 earnings per share for the current fiscal year.

Johnson & Johnson Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, December 8th. Shareholders of record on Tuesday, November 24th will be given a $1.34 dividend. The ex-dividend date of this dividend is Tuesday, November 24th. This represents a $5.36 dividend on an annualized basis and a yield of 1.9%. Johnson & Johnson’s dividend payout ratio (DPR) is currently 81.21%.

Wall Street Analyst Weigh In

JNJ has been the topic of several research reports. Argus set a $300.00 target price on Johnson & Johnson in a research note on Wednesday, July 29th. UBS Group set a $270.00 target price on Johnson & Johnson in a research report on Wednesday, October 14th. Weiss Ratings lowered shares of Johnson & Johnson from a “buy (b+)” rating to a “buy (b-)” rating in a research note on Friday, October 23rd. Raymond James Financial set a $280.00 price target on shares of Johnson & Johnson in a research report on Monday, August 3rd. Finally, Royal Bank Of Canada lowered their price objective on shares of Johnson & Johnson from $290.00 to $280.00 and set an “outperform” rating for the company in a research note on Wednesday, October 14th. One equities research analyst has rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and eight have issued a Hold rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $275.92.

Johnson & Johnson Profile

Johnson & Johnson is a global healthcare company that develops and sells prescription medicines and medical technologies. Its business is organized around two segments: Innovative Medicine and MedTech. Innovative Medicine develops treatments in areas including oncology, immunology, neuroscience, cardiovascular and metabolic disease, and pulmonary hypertension. MedTech provides products and technologies for fields such as surgery, orthopedics, and vision care. Founded in 1886, Johnson & Johnson serves patients and healthcare professionals in markets around the world.